CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit
23 Abril 2024 - 4:00AM
CDR-Life to Present Tumor Targeting Capabilities of M-gager®
Platform at the TCR-Based Therapies for Solid Tumors Summit
CDR-Life Inc. today announced a presentation on its proprietary
antibody-major histocompatibility complex (MHC) technology for the
development of highly specific T-cell engagers (TCE) at the
TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25
in Boston, Massachusetts.
The presentation will discuss how antibodies targeting tumor
peptides on the MHC enable T-cells access to an untapped reservoir
of intracellular tumor antigens and will highlight the M-gager®
technology’s ability to leverage the potency, versatility and
manufacturability of antibodies to revolutionize cancer
immunotherapy.
Presentation DetailsTitle: Unlocking Tumor
Eradication with Antibody-MHC T Cell Engagers Presenter: Leonardo
Borras, Chief Scientific Officer Date: April 23, 2024
About CDR-LifeCDR-Life is developing powerful
T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our
integrated antibody-based TCE platform unlocks access to a wide
range of cancer antigens. We are leveraging this platform to
advance a pipeline of potent and selective TCE therapeutics
targeting intracellular and surface tumor antigens. With a team of
proven drug development experts and backed by leading
cross-Atlantic investors, we are working to empower patients’ own
immune systems to eliminate tumors.